Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: Comparison with those in patients with type I diabetes mellitus

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 1-23

  Lee, Joo H ^a,b   Yanga, Si H ^a   Oha, Jung M ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

Author keywords

Alloxan; Cytochrome P450 isozymes; Diabetes mellitus; Pharmacokinetics; Streptozocin

Indexed keywords

ALLOXAN; AMINOPHENAZONE; AZOSEMIDE; CHLORZOXAZONE; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450; DIAZEPAM; DICLOFENAC; DIGOXIN; DOXORUBICIN; FLUOROURACIL; FUROSEMIDE; GALARUBICIN; HEXOBARBITAL; IPRIFLAVONE; ITRACONAZOLE; LIDOCAINE; METFORMIN; OLTIPRAZ; OMEPRAZOLE; OXYCODONE; PHENYTOIN; PROPOFOL; STREPTOZOCIN; TELITHROMYCIN; THEOPHYLLINE; TORASEMIDE; UDENAFIL; UNINDEXED DRUG;

AREA UNDER THE CURVE; BILE; BRAIN; CONJUGATION; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE; KIDNEY; KIDNEY METABOLISM; LIVER; LIVER BLOOD FLOW; LIVER METABOLISM; LUNG; NONHUMAN; NORTHERN BLOTTING; REVIEW; STREPTOZOCIN DIABETES; TESTIS; WESTERN BLOTTING;

ALLOXAN; ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HUMANS; PHARMACEUTICAL PREPARATIONS; RATS; SPECIES SPECIFICITY; STREPTOZOCIN;

EID: 77949527303     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0001     Document Type: Review

References (215)

1. Pickup JC, Williams G. Textbook of Diabetes, Vol. 1. Oxford, UK: Blackwell Scientific Publications, 1991: 151-155.
2. Watkins JB III, Sanders RA. Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 1995; 47: 1-23.
3. Ioannides C. Chapter 12. Expression of cytochrome P450 protein in disease. In: Cytochrome P450. Metabolic and toxicological aspects. Boca Raton, New York, London, Tokyo: CRC Press, 1996: 301-327.
4. Watkins JB III, Sherman SE. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 1992; 260: 1337-1343.
5. Choi YH et al. Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci 2008; 97: 5363-5375.
6. Ackerman DM, Leibman KC. Effect of experimental diabetes on drug metabolism in the rat. Drug Metab Dispos 1977; 5: 405-410.
7. Reinke LA et al. Altered activity of hepatic mixed-function mono-oxygenase enzymes in streptozotocin-induced diabetic rats. Xenobiotica 1978; 8: 611-619.
8. Ogata M et al. Effect of streptozotocin-induced diabetes on cyclosporine A disposition in rats. Biol Pharm Bull 1996; 19: 1586-1590.
9. Choi YH et al. Effects of diabetes mellitus induced by alloxan on the pharmacokinetics of metformin in rats: restoration of pharmacokinetic parameters to the control state by insulin treatment. J Pharm Pharm Sci 2008; 11: 88-103.
10. Song BJ et al. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol 1987; 1: 542-547.
11. Dong Z et al. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys 1988; 263: 29-35.
12. Ma Q et al. Similarities and differences in the regulation of hepatic cytochrome P-450 enzymes by diabetes and fasting in male rats. Biochem Pharmacol 1989; 38: 3179-3184.
13. Yamazoe Y et al. Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Arch Biochem Biophys 1989; 268: 567-575.
14. Barnett CR et al. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 1990; 268: 765-769.
15. Barnett CR et al. Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins. Biochem Pharmacol 1993; 45: 313-319.
16. Thummel KE, Schenkman JB. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 1990; 37: 119-129.
17. Shimojo N et al. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 1993; 46: 621-627.
18. Raza H et al. Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenase and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol 1996; 52: 1639-1642.
19. Raza H et al. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol 2000; 14: 131-139.
20. Sakuma T et al. Different expression of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic mouse and rat. Xenobiotica 2001; 31: 223-237.
21. Kim YC et al. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J PharmSci 2005; 26: 114-123.
22. Sindhu RK et al. Differential regulation of hepatic cytochrome P450 monooxygenases in streptozotocin-induced diabetic rats. Free Radic Res 2006; 40: 921-928.
23. Ahn CY et al. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Br J Pharmacol 2009; 156: 1019-1028.
24. Al-Turk WA et al. Activities of hepatic and extrahepatic microsomal mixed function oxidase enzymes in diabetic and gonadectomized- diabetic rats. Gen Pharmacol 1981; 12: 345-350.
25. Al-Turk WA et al. Altered activities of hepatic and extrahepatic microsomal mixed function oxidase enzymes in diabetic and adrenalectomized diabetic rats. Pharmacology 1981; 23: 337-345.
26. Vega P et al. Comparison of alloxan and streptozotocin induced diabetes in rats: differential effects on microsomal drug metabolism. Gen Pharmacol 1993; 24: 489-495.
27. Li L, Zhang Y. Changes of CYP2E1 activity in diabetic rat model. Yao Xue Xue Bao (Acta Pharmaceutica Sinica) 1998; 33: 891-895.
28. Borbás T et al. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur J Pharm Sci 2006; 28: 51-58.
29. Pachecka J et al. The effect of short-term alloxan-induced diabetes on the activity of drug metabolizing enzymes. Acta Pol Pharm 1993; 50: 435-439.
30. Suchocka Z et al. Activity of glutathione-dependent enzymes in long term diabetes. I. Activity of glutathione S-transferase and glutathione peroxidase in the liver of alloxan induced diabetic rats. Acta Pol Pharm 1995; 52: 207-211.
31. Suchocka Z et al. Activity of glutathione-dependent enzymes in long term diabetes. II. Glutathione contents and activity of glutathione-dependent enzymes: S-transferase and peroxidase in the kidney cytosol of alloxan-induced diabetic rats. Acta Pol Pharm 1995; 52: 213-217.
32. Gupta RR et al. Cytochrome P450-dependent oxidation and glutathione conjugation of xenobiotics in alloxan-induced diabetic rat. Res Commun Mol Pathol Pharmacol 1997; 98: 231-236.
33. Price VF, Jollow DJ. Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity. Biochem Pharmacol 1986; 35: 687-695.
34. Wang Z et al. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003; 55: 77-85.
35. Matzke GR et al. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 2000; 20: 182-190.
36. Sotaniemi EA et al. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 2002; 90: 155-160.
37. Kashuba AD, Bertino JS Jr. Mechanisms of drug interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. 1st edn. Totowa: Humana Press, 2000: 13-38.
38. Chang FYL et al. Hyperglycaemia is responsible for the inhibited gastrointestinal transit in the early diabetic rat. Acta Physiol Scand 1995; 155: 457-462.
39. Xie W et al. A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit. Eur J Pharmacol 2005; 510: 113-120.
40. Park JH et al. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos 1998; 19: 357-364.
41. Baek HW et al. Pharmacokinetics of chlorzoxazone in rats with diabetes: induction of CYP2E1 on 6-hydroxychlorzoxazone formation. J Pharm Sci 2006; 95: 2452-2462.
42. Lee JH, Lee MG. Telithromycin pharmacokinetics in rats with diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 2008; 25: 1915-1924.
43. Kim YC et al. Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.. Antimicrob Agents Chemother 2005; 49: 2528-2532.
44. Kim YC et al. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. J Pharm Sci 2004; 93: 2374-2387.
45. Kim YC et al. Pharmacokinetics of phenytoin and its metabolite, 4′-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin. Biopharm Drug Dispos 2008; 29: 51-61.
46. Nadai M et al. Effect of diabetes on disposition and renal handling of cefazolin in rats. Drug Metab Dispos 1990; 18: 565-570.
47. Anwana AB, Garland HO. Intracellular dehydration in the rat made diabetic with streptozotocin: effects of infusion. J Endocrinol 1991; 128: 333-337.
48. Sato H et al. Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res 1991; 8: 563-569.
49. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390.
50. Hill MA, Larkins RG. Alterations in distribution of cardiac output in experimental diabetes in rats. Am J Physiol 1989; 257: H571-H580.
51. Lucas PD, Foy JM. Effects of experimental diabetes and genetic obesity on regional blood flow in the rat. Diabetes 1977; 26: 786-792.
52. Chiou WL. A new simple approach to study the effect of changes in urine flow and/or urine pH on renal clearance and its applications. Int J Clin Pharmacol Ther Toxicol 1986; 24: 519-527.
53. Ryan JP, Irwin JA. Practical studies on urine demonstrating principles of clinical and veterinary significance. Biochem Mol Biol Educ 2002; 30: 98-100.
54. Nakashima E et al. Comparative pharmacokinetics of cefoperazone and cephradine in untreated streptozotocin diabetic rats. Drug Metab Dispos 1992; 20: 730-735.
55. Carnovale CE et al. Bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol 1986; 35: 2625-2628.
56. Park JM et al. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 1996; 93: 343-352.
57. Kim SH et al. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos 1998; 19: 303-308.
58. Warren S et al. The Pathology of Diabetes Mellitus. 4th edn. Philadelphia: Lea & Febiger, 1966; 458-467.
59. Evan AP et al. The effect of streptozotocin and streptozotocin-induced diabetes on the kidney. Ren Physiol 1984; 7: 78-89.
60. Nowicki MT et al. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab Lett 2008; 2: 11-17.
61. van Waarde WM et al. Differential effects of streptozotocin- induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 2002; 122: 1842-1852.
62. Liu H et al. Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res 2006; 1123: 245-252.
63. Maeng HJ et al. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 2007; 35: 1996-2005.
64. Kameyama N et al. Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim Biophys Acta 2008; 1782: 355-360.
65. Koehn J et al. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect Disord Drug Targets 2008; 8: 109-118.
66. Gwilt PR et al. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991; 20: 477-490.
67. O'Connor P, Feely J. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin Pharmacokinet 1987; 13: 345-364.
68. Kropp H et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob Agents Chemother 1982; 22: 62-70.
69. Kim SH et al. Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. Antimicrob Agents Chemother 1999; 43: 2524-2527.
70. Kim SH et al. Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits. Biopharm Drug Dispos 1999; 20: 125-129.
71. Lewis DFV. P450. Substrate specificity and metabolism. In: Lewis DFV, ed. Cytochromes P450. Structure, Function and Mechanism. Bristol: Talyor & Francis, 1996: 123.
72. Levy RH, et al. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Company, 2000.
73. Ortiz de Montellano PR. Cytochrome P450. Structure, Mechanism, and Biochemistry, 3rd edn. New York and London: Plenum Press, 2004.
74. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1984; 11: 623-640.
75. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
76. Mitruka BM, Rawnsley HM. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd edn. New York: Masson Publishing, 1982.
77. Choi YH et al. Pharmacokinetics of intravenous methotrexate in mutant Nagase analbuminemic rats. Biopharm Drug Dispos 2007; 28: 385-392.
78. Tsyrlov IB, Gerasimov KE. Aminopyrine-N-demethylase. I. Directed modification of substrates' structure as a way of production of inducer of the monooxygenase isoform P-450b. Eur J Drug Metab Pharmacokinet 1991; 16: 207-212.
79. Imaoka S et al. Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Arch Biochem Biophys 1988; 265: 159-170.
80. Zysset T, Sommer L. Diabetes alters drug metabolism - in vivo studies in a streptozotocin-diabetic rat model. Experientia 1986; 42: 560-562.
81. Toda A et al. Effects of experimental diabetes on aminopyrine metabolism in rats. Xenobiotica 1987; 17: 1075-1083.
82. Chawalit K et al. Comparative effects of diabetogenic agents on hepatic drug metabolism. Drug Metab Dispos 1982; 10: 81-86.
83. Volz M, Kellner HM. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 1980; 10(Suppl. 2): 299S-308S.
84. Zysset T, Tlach C. Altered liver function in diabetes: model experiments with aminopyrine in the rat. J Pharmacol Exp Ther 1987; 240: 271-276.
85. Chen L, Yang CS. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sci 1996; 58: 1575-1585.
86. Conney AH, Burns JJ. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 1960; 128: 340-343.
87. Rockich K, Blouin R. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 1999; 27: 1074-1077.
88. Kim YG et al. Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein - calorie malnutrition. Biopharm Drug Dispos 2002; 23: 121-129.
89. Ahn CY et al. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. J Pharm Sci 2003; 92: 1604-1613.
90. Chung W-S et al. Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sci 2003; 73: 253-263.
91. Moon YJ et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003; 31: 776-784.
92. Peter R et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 1990; 3: 566-573.
93. Minors JO, McKinnon RA. CYP1A. In: Levy RH et al. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Company, 2000: 61-74.
94. Yang KH et al. Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: involvement of CYP1A1/2 in the formation of 1,3-DMU. J Pharm Pharmacol 2008; 60: 45-53.
95. Yang KH et al. Time-dependent effects of Klebsiella pneumoniae endotoxin (KPLPS) on the pharmacokinetics of theophylline in rats: return of the parameters in 96-hour KPLPS rats to the control levels. Drug Metab Dispos 2008; 36: 811-815.
96. Korrapati MR et al. Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1995; 57: 413-418.
97. Adithan C et al. Effect of type I diabetes mellitus on theophylline elimination. Med Sci Res 1988; 16: 427-428.
98. Nakamoto T et al. Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Drug Metab Dispos 1997; 25: 296-300.
99. Gawronska-Szklarz B et al. Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. Pol J Pharmacol 2003; 55: 619-624.
100. Huang L et al. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague - Dawley rats: influence of streptozotocin-induced diabetes. Pharm Res 2005; 22: 1489-1498.
101. Lee JH, Lee MG. Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin. Biopharm Drug Dispos 2007; 28: 157-166.
102. Lee JH, Lee MG. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability. J Pharm Pharm Sci 2007; 10: 37-50.
103. Ahn CY et al. Effects of cysteine on the pharmacokinetics of intravenous clarithromycin in rats with protein - calorie malnutrition. Life Sci 2003; 73: 1783-1794.
104. Lee AK et al. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 2004; 25: 273-282.
105. Lee WI et al. Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. Biopharm Drug Dispos 1997; 18: 753-767.
106. Smith DE et al. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos 1980; 8: 337-342.
107. Yang KH et al. Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1, and 3A2 in furosemide metabolism. J Pharm Pharmacol 2009; 61: 1-8.
108. Kim EJ et al. Gastrointestinal first-pass effect of furosemide in rats. J Pharm Pharmacol 2000; 52: 1337-1343.
109. Bae SK et al. Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein - calorie malnutrition. J Pharm Sci 2004; 93: 2388-2398.
110. Lee DY et al. Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. Biopharm Drug Dispos 2005; 26: 173-182.
111. Kim YC et al. Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. Biopharm Drug Dispos 2005; 26: 371-378.
112. Lee DY et al. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. Int J Pharm 2005; 298: 38-46.
113. Asano T et al. Disposition of azosemide. I. Distribution, metabolism and excretion following intravenous administration to rats. Yakugaku Zasshi 1984; 104: 1181-1190.
114. Schuchmann HW et al. Pharmacokinetics of azosemide in patients with T-drain after cholecystectomy. Arzneimittelforschung/Drug Res 1992; 42: 812-814.
115. Lee SH, Lee MG. Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. Biopharm Drug Dispos 1997; 18: 371-386.
116. Park KJ et al. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. J Pharm Pharmacol 1996; 48: 1093-1097.
117. Kim J et al. Liver and gastrointestinal first-pass effects of azosemide in rats. J Pharm Pharmacol 1997; 49: 878-883.
118. Suh OK et al. Pharmacokinetics and pharmacodynamics of azosemide. Biopharm Drug Dispos 2003; 24: 275-297.
119. Lee DY et al. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. Biopharm Drug Dispos 2006; 27: 209-218.
120. Watanabe K et al. First-pass metabolism of omeprazole in rats. J Pharm Sci 1994; 83: 1131-1134.
121. Lee DY et al. Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharm Sci 2007; 10: 420-433.
122. Bae SK et al. Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous oltipraz in rats. J Pharm Pharmacol 2005; 57: 443-452.
123. Bieder A et al. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittelforschung Drug Res 1983; 33: 1289-1297.
124. Bae SK et al. Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein - calorie malnutrition. J Pharm Sci 2005; 94: 1484-1493.
125. Bae SK et al. Hepatic and intestinal first-pass effects of oltipraz in rats. Biopharm Drug Dispos 2005; 26: 129-134.
126. Bae SK et al. Pharmacokinetics of oltipraz in rats with diabetes mellitus induced by alloxan or streptozotocin. Life Sci 2006; 78: 2287-2294.
127. Bae SK et al. Pharmacokinetics and therapeutic effects of oltipraz after consecutive or intermittent oral administration in rats with liver cirrhosis induced by dimethylnitrosamine. J Pharm Sci 2006; 95: 985-997.
128. Kang KW et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB J 2002; 16: 1988-1990.
129. Kim YC et al. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. Biopharm Drug Dispos 2005; 26: 233-241.
130. Shim HJ et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 2003; 92: 2185-2195.
131. Chung HJ et al. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol 2006; 58: 449-457.
132. Lee DY et al. Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. Eur J Pharm Sci (in press).
133. Kim SH, Lee MG. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. Life Sci 2002; 70: 1299-1315.
134. Kharash ED, Ihrahim AE. CYP2C. In: Levy RH et al. eds. Metabolic Drug Interactions. Philadelphia: Lippincott Williams & Wilkins, a Wolters Kluwer Company, 2000: 78.
135. Yamazaki H et al. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. Drug Metab Dispos 2001; 29: 427-434.
136. Rane A et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 1977; 200: 420-424.
137. Adithan C et al. Increased elimination of phenytoin in type I undernourished diabetic patients. Indian J Pharmacol 1990; 22: 211-215.
138. Adithan C et al. Influence of type I and type II diabetes mellitus on phenytoin steady-state levels. Int J Clin Pharmacol Ther Toxicol 1991; 29: 310-313.
139. Masubuchi Y et al. Mechanism-based inactivation of CYP2C11 by diclofenac. Drug Metab Dispos 2001; 29: 1190-1195.
140. Kim YC et al. Pharmacokinetics of diclofenac in rats with diabetes mellitus induced by alloxan or streptozotocin. Biopharm Drug Dispos 2006; 27: 85-92.
141. Kuhlmann J. Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin. Clin Pharmacol Ther 1985; 38: 667-673.
142. Salphati L, Benet LZ. Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 1999; 29: 171-185.
143. Harrison LI, Gibaldi M. Pharmacokinetics of digoxin in the rat. Drug Metab Dispos 1976; 4: 88-93.
144. Doherty JE, Perkins WH. Studies with tritiated digoxin in human subjects after intravenous administration. Am Heart J 1962; 63: 528-536.
145. 3H]digoxin and its metabolites in rats. Eur J Pharmacol 1974; 29: 43-51.
146. Yamazaki H et al. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab Dispos 2006; 34: 1803-1805.
147. Leal N et al. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. J Pharm Pharmacol 2005; 57: 317-325.
148. Raoof AA et al. In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Pharm Res 1996; 13: 891-895.
149. Bachur NR, Gee M. Microsomal reductive glycosidase. J Pharmacol Exp Ther 1976; 197: 681-686.
150. Lovless H et al. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978; 38: 593-598.
151. Goeptar AR et al. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 1993; 44: 1267-1277.
152. Lee HJ, Lee MG. Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res Commun Mol Pathol Pharmacol 1999; 105: 87-96.
153. Lee HJ et al. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 1995; 89: 165-178.
154. Prueksaritanont T et al. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metab Dispos 1993; 21: 730-737.
155. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986; 18: 25-34.
156. Christians U et al. Measurement of cyclosporine and 18 metabolites in blood, bile, and urine by high-performance liquid chromatography. Transplant Proc 1988; 20: 609-613.
157. Brunner LJ et al. Cyclosporine pharmacokinetics and effect in the type I diabetic rat model. Eur J Drug Metab Pharmacokinet 1989; 14: 287-292.
158. D'Souza MJ et al. Pharmacokinetics of cyclosporine in streptozotocin-induced diabetic rats. Drug Metab Dispos 1988; 16: 778-780.
159. Choi YH et al. Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos 2005; 26: 93-98.
160. Yoon EJ et al. Pharmacokinetics, tissue distribution, and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine. Int J Pharm 1994; 109: 181-187.
161. Kim YG et al. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein - calorie malnutrition rats. Biopharm Drug Dispos 1996b; 17: 183-195.
162. Choi YJ et al. Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 1996; 94: 181-192.
163. Shin JH et al. Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect. Antimicrob Agents Chemother 2004; 48: 1756-1762.
164. Arredondo G et al. Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J Antimicrob Chemother 1999; 43: 305-307.
165. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-371.
166. Sirtori CR et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683-693.
167. Tucker GT et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-246.
168. Choi YH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin. Br J Pharmacol 2006; 149: 424-430.
169. Choi YH et al. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 2006; 95: 2543-2552.
170. Choi YH et al. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats: involvement of CYP1A1/2, 2B1/2, 2D1, and 3A1/2. Presented at Annual Convention of the Pharmaceutical Society of Korea: April 30-May 4 2008; International Convention Center, Jeju, South Korea, p. 344.
171. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994; 4: 359-362.
172. Ishihara K et al. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol 2000; 52: 1023-1029.
173. 14C]diazepam in the streptozotocin-diabetic rat. Xenobiotica 1984; 14: 751-760.
174. Ryan DE, Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 1990; 45: 153-239.
175. Vermeulen NPE et al. Disposition of hexobarbital in the rat. Estimation of "first-pass" elimination and influence of ether anesthesia. J Pharmacol Exp Ther 1983; 226: 201-205.
176. Sugioka N et al. Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats. Biopharm Drug Dispos 2008; 29: 469-479.
177. Emami J et al. Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. Pharm Res 1998; 15: 897-903.
178. Chung SY et al. Pharmacokinetics of a new proton-pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with streptozotocin-induced diabetes mellitus. J Pharm Pharmacol 1999; 51: 929-934.
179. Moon CH et al. Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus. Res Commun Mol Pathol Pharmacol 1998; 101: 147-158.
180. 3H]insulin in streptozotocin diabetic rats. J Clin Invest 1981; 67: 673-680.
181. Kuo WL et al. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology 1993; 132: 604-611.
182. Morita M et al. Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins. Cell Struct Funct 2000; 25: 309-315.
183. Adithan C et al. Effect of diabetes mellitus on salivary paracetamol elimination. Clin Exp Pharmacol Physiol 1988a; 15: 465-471.
184. Lin JH et al. Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther 1985; 235: 402-406.
185. Lin JH et al. Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats. Drug Metab Dispos 1985; 13: 321-326.
186. Lin JH et al. Effect of experimental diabetes on elimination kinetics of diflunisal in rats. Drug Metab Dispos 1989; 17: 147-152.
187. Volland C, Benet LZ. In vitro enantioselective glucuronidation of fenoprofen. Pharmacology 1991; 43: 53-60.
188. Sattari S, Jamali F. Involvement of the rat gut epithelial and muscular layer, and microflora in chiral inversion and acylglucuronidation of R-fenoprofen. Eur J Drug Metab Pharmacokinet 1997; 22: 97-101.
189. Poggi JC et al. Enantioselective kinetic disposition of fenoprofen in rats with experimental diabetes or adjuvant-induced arthritis.
190. Le Guellec C et al. Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: effect of different drugs. Anesth Analg 1995; 81: 855-861.
191. Poggi JC et al. Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. J Clin Pharmacol 2006; 46: 1328-1336.
192. Kang HE et al. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up. J Pharm Sci 2009 (in press).
193. Kim JY et al. Renal dehydropeptidase-I (DHP-I) stability and pharmacokinetics of DA-1131, a new carbapenem antibiotic. In: Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology. Seoul National University, Seoul, Korea. 1996; 238.
194. Kimura T et al. Disposition of recombinant human insulin-like growth factor-I in normal and hypophysectomized rats. Biol Pharm Bull 1994; 17: 310-315.
195. Higaki K et al. Pharmacokinetics of recombinant human insulin-like growth factor-I in diabetic rats. Drug Metab Dispos 1997; 25: 1324-1327.
196. Renard C et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997; 52: 54-62.
197. Tamai I et al. Membrane potential-dependent and carrier-mediated transport of cefpiramide, a cephalosporin antibiotic, in canalicular rat liver plasma membrane vesicles. J Pharmacol Exp Ther 1990; 253: 537-544.
198. Gin H et al. Does glycemic level influence the pharmacokinetics of an antibiotic (cefoperazone)? Diabete Metab 1991; 17: 417-420.
199. Tsuji A et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci 1983; 72: 1239-1252.
200. Coombes JD. Metabolism of cefotaxime in animals and humans. Rev Infect Dis 1982; 4(Suppl.): S325-S332.
201. Li QZ, Zhang CL. The pharmacokinetics and pharmacodynamics of cefotaxime in experimental diabetic rats. Acta Pharmaceutica Sinica 1995; 30: 495-499.
202. Beyer-Mears A et al. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus. Pharmacology 1996; 52: 292-302.
203. Schneider RP et al. Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats. Drug Metab Dispos 1998; 26: 1149-1159.
204. Inskeep PB et al. Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharm Res 1991; 8: 1511-1515.
205. Mehvar R. Effect of experimental diabetes mellitus on the pharmacokinetics of atenolol enantiomers in rats. J Pharm Sci 1991; 80: 207-211.
206. Barbera A et al. Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism. J Biol Chem 1994; 269: 20047-20053.
207. Barbera A et al. Effects of tungstate in neonatally streptozotocin-induced diabetic rats: mechanism leading to normalization of glycaemia. Diabetologia 1997; 40: 143-149.
208. Le Lamer S et al. Pharmacokinetics of sodium tungstate in rat and dog: a population approach. J Pharmacol Exp Ther 2000; 294: 714-721.
209. Ando A et al. Affinity of the elements in group VI of the periodic table to tumors and organs. Radioisotopes 1976; 25: 630-636.
210. Le Lamer-Dechamps S et al. Influence of food and diabetes on pharmacokinetics of sodium tungstate in rat. Int J Pharm 2002; 248: 131-139.
211. Bae SK et al. Excretion and metabolism of DA-7867, a new oxazolidinone, in rats. Biopharm Drug Dispos 2005; 26: 67-75.
212. Bae SK et al. Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. Eur J Pharm Sci 2005; 25: 337-345.
213. Mulay S, Varma DR. Influence of streptozotocin-diabetes on the pharmacokinetics, placental transfer and tissue localization of dexamethasone in rats. Br J Pharmacol 1984; 83: 139-144.
214. Watkins JB 3rd, Dykstra TP. Alterations in biliary excretory function by streptozotocin-induced diabetes. Drug Metab Dispos 1987; 15: 177-183.
215. Watkins JB 3rd, Noda H. Biliary excretion of organic anions in diabetic rats. J Pharmacol Exp Ther 1986; 239: 467-473.